Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 April 2023 - 10:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 28, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Novo
Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2023
Bagsværd,
Denmark, 28 April 2023 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required
to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes
therein have occurred.
Referring to Company
Announcement no 27/2023 dated 26 April 2023, please find below a statement regarding the total number of voting rights and share capital
in Novo Nordisk A/S as per 28 April 2023.
|
Number
of shares (of DKK 0.20 each) |
Share
capital (nominal value, DKK) |
Number
of votes1 |
A shares |
537,436,000 |
107,487,200 |
107,487,200,000 |
B shares |
1,717,564,000 |
343,512,800 |
34,351,280,000 |
Total |
2,255,000,000 |
451,000,000 |
141,838,480,000 |
1
Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.20 carries
200 votes and each B share of DKK 0.20 (the present denomination of the company's shares) carries 20 votes. Treasury shares are included
in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S.
Page 2 of 2
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working
to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 28 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 28, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024